Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 190.83% | 69.11% | -11.98% | -62.57% | -83.63% |
| Total Other Revenue | 98.29% | 98.29% | -986.79% | -- | -- |
| Total Revenue | 1,901.57% | 234.16% | -31.04% | -82.19% | -97.63% |
| Cost of Revenue | -99.79% | -99.74% | -67.30% | -58.64% | -29.77% |
| Gross Profit | 334.43% | 440.17% | 18.94% | -109.21% | -129.78% |
| SG&A Expenses | -65.26% | -20.26% | -38.62% | -29.22% | -24.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 197.92% | 197.92% | -267.59% | -- | -- |
| Total Operating Expenses | -67.79% | -33.07% | -52.96% | -43.42% | -34.87% |
| Operating Income | 74.28% | 39.08% | 54.69% | 40.71% | 28.64% |
| Income Before Tax | 74.24% | 46.21% | 54.97% | 28.28% | 19.42% |
| Income Tax Expenses | -143.16% | -143.16% | -93.79% | -93.95% | -71.06% |
| Earnings from Continuing Operations | 76.13% | 49.21% | 58.32% | 33.80% | 23.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -20.01% | -18.51% | 430.24% | 534.14% | 495.98% |
| Net Income | 79.41% | 51.15% | 64.00% | 40.36% | 28.18% |
| EBIT | 74.28% | 39.08% | 54.69% | 40.71% | 28.64% |
| EBITDA | 74.69% | 39.30% | 54.87% | 40.84% | 28.69% |
| EPS Basic | 92.26% | 82.09% | 87.15% | 67.32% | 50.69% |
| Normalized Basic EPS | 92.80% | 81.71% | 88.85% | 67.31% | 50.61% |
| EPS Diluted | 91.97% | 81.85% | 86.96% | 67.25% | 50.64% |
| Normalized Diluted EPS | 92.80% | 81.71% | 88.85% | 67.31% | 50.61% |
| Average Basic Shares Outstanding | 118.28% | 169.00% | 187.16% | 141.18% | 82.86% |
| Average Diluted Shares Outstanding | 118.28% | 169.00% | 187.16% | 141.18% | 82.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |